21 patents
Utility
Crystalline Forms of a Farnesoid X Receptor Agonist
11 May 23
Described herein is the farnesoid X receptor agonist, 4-((4-(1-(tert-butyl)-1H-pyrazol-4-yl)pyridin-2-yl)((4-(4-methoxy-3-methylphenyl)bicyclo[2.2.2]octan-1-yl)methyl)carbamoyl)cyclohexyl 3-hydroxyazetidine-trans-1-carboxylate, including crystalline forms and pharmaceutically acceptable salts, solvates, and formulations thereof.
Nicholas D. SMITH, Robert MANSFIELD
Filed: 17 Mar 21
Utility
Farnesoid X Receptor Agonists for the Treatment of Disease
27 Apr 23
Described herein is the use of farnesoid X receptor (FXR) agonists, alone or in combination with additional therapies, in the treatment or prevention of diseases, conditions, or disorders that would benefit from therapy with a FXR agonist.
Kenneth SONG, Hubert CHEN, Brandee WAGNER, Nicholas D. SMITH
Filed: 17 Mar 21
Utility
ub3xezed1ph2fxbkva3dtc4h7iwpblaljszqclpsws
20 Apr 23
Described herein are pharmaceutical formulations of a farnesoid X receptor agonist, 4-((4-(1-(tert-butyl)-1H-pyrazol-4-yl)pyridin-2-yl)((4-(4-methoxy-3-methylphenyl)bicyclo[2.2.2]octan-1-yl)methyl)carbamoyl)cyclohexyl 3-hydroxyazetidine-trans-1-carboxylate, and methods of using such pharmaceutical formulations in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Robert MANSFIELD
Filed: 17 Mar 21
Utility
w1zq 4fbsewb8m9m75rn1a61
13 Oct 22
Described herein are combination therapies with farnesoid X receptor (FXR) agonists, and methods of using such pharmaceutical compositions in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Kenneth SONG, Hubert CHEN, Brandee WAGNER
Filed: 9 Jun 22
Utility
mdn3k4853y87ns7ndobo5x6fzepx24nhmn j6lqr0c9obehg40yrcg
24 Mar 22
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA, Karensa L. DOUGLAS, Andiliy G. LAI
Filed: 30 Nov 21
Utility
0z7tf3cwo6n6jd7rkg5awbkv4zlwhjdq3 xiy2
17 Mar 22
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA
Filed: 22 Nov 21
Utility
ktim67jb9gjczcd2mwas
24 Feb 22
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA, Andiliy G. LAI, Karensa L. DOUGLAS
Filed: 17 Sep 19
Utility
8evm4chx2t5mz43xnp1widefkqra37zb wh82efwg0daf0uaoh2jlovnrqxb
24 Feb 22
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK
Filed: 17 Sep 19
Utility
xr64c9dzuvtg80ymipacfp741sf8iixu3m n62o73ywwyngi9r2zg78qbfu
17 Feb 22
Described herein are combination therapies with famesoid X receptor (FXR) agonists, and methods of using such pharmaceutical compositions in the treatment of conditions, diseases, or disorders associated with famesoid X receptor activity.
Kenneth SONG, Hubert CHEN, Brandee WAGNER, Nicholas D. SMITH
Filed: 17 Sep 19
Utility
rgkagip kunmlp5zp7k35
6 Jan 22
Described herein are compounds that are semicarbazide-sensitive amine oxidase (SSAO) inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating or preventing a liver disease or condition.
Nicholas D. SMITH, Andrew R. HUDSON, Mi CHEN, Johnny Y. NAGASAWA, Iriny BOTROUS
Filed: 23 Oct 19
Utility
o2t2ewkj6py9tuq5fikor53pvvbbam931d
23 Dec 21
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Karensa L. DOUGLAS, Andiliy G. LAI
Filed: 16 Jun 21
Utility
yrizhu3ykd1gsvsvf0smasta9djdruckaak70
11 Nov 21
Described herein is the farnesoid X receptor agonist, trans-N-(3-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl)-4-hydroxy-N-((trans-4-(4-methoxy-3-methyl phenyl)cyclohexyl)methyl)cyclohexane-carboxamide, including crystalline forms and pharmaceutically acceptable salts, solvates, and formulations thereof.
Nicholas D. SMITH, Robert MANSFIELD
Filed: 17 Sep 19
Utility
h930e34h6hmz41af5p2vd52ayx7jdv36zmniv7uvax03id0vmyhjz3
30 Sep 21
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA
Filed: 19 Jan 21
Utility
w5h8e8crkb6swdp5d61705qn1mwstauigyl4kfsx7gtccreb2t6r9l
4 Feb 21
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA
Filed: 12 May 20
Utility
o0ghf14yjpwlotk5avgtuz7f4to8s65b372eu5dpbfz5c8cdhvy72t3
16 Sep 20
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Stephen P. GOVEK, Johnny Y. NAGASAWA
Filed: 27 May 20
Utility
ksnqtg94mprt3t7w9hdwlma7w8s289dcxewwwb2lxtx4czuma k7xads0zf0
10 Jun 20
Described herein are compounds that are semicarbazide-sensitive amine oxidase (SSAO) inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating or preventing a liver disease or condition.
Nicholas D. Smith, Andrew R. Hudson, Mi Chen, Johnny Y. Nagasawa, Iriny Botrous
Filed: 13 Feb 20
Utility
88pu9gc57wb2ju03x4xk2j7fbf0ox09 unbm9e3bygu665e3d
29 Apr 20
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA, Andiliy G. LAI
Filed: 13 Mar 18
Utility
kb2fjhlcev1mfpxgayiwywbvh9wiqzc7gj7y3zzbsexe2k74fn3
29 Apr 20
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA
Filed: 13 Mar 18
Utility
anwubnhptynv6me1wax2eod5j1o2ljkqlwbhhi8
29 Apr 20
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA
Filed: 13 Mar 18
Utility
cg07kyihs8orj0iq89zst1ivxpq5e748626e8nz86f yjuxwnxp5594
29 Apr 20
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA, Karensa L. Douglas
Filed: 13 Mar 18